Effect of cellular quiescence on the success of targeted CML therapy

PLoS ONE

Volumn 2, Issue 10, 2007, Pages

  Komarova, Natalia L ^a   Wodarz, Dominik ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CELL ACTIVATION; CELL DEATH; CELL FUNCTION; CELL KILLING; CELL KINETICS; CELL POPULATION; CELL QUIESCENCE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG TARGETING; DRUG TREATMENT FAILURE; MATHEMATICAL MODEL; OUTCOMES RESEARCH; BIOLOGICAL MODEL; DRUG RESISTANCE; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; MUTATION; ONCOLOGY; PATHOLOGY; PROBABILITY; STATISTICS; THEORETICAL MODEL;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MODELS, THEORETICAL; MUTATION; PIPERAZINES; PROBABILITY; PYRIMIDINES; STOCHASTIC PROCESSES;

EID: 41549104612     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000990     Document Type: Article

References (46)

1. Pelayo R, Miyazaki K, Huang J, Garrett KP, Osmond DG, et al. (2006) Cell cycle quiescence of early lymphoid progenitors in adult bone marrow. Stem Cells 24: 2703-2713.
2. Arai F, Suda T (2007) Maintenance of quiescent hematopoiefic stem cells in the osteoblastic niche. Ann N Y Acad Sci.
3. Moore KA, Lemischka IR (2006) Stem cells and their niches. Science 311: 1880-1885.
4. Cheshier SH, Morrison SJ, Liao X, Weissman IL (1999) In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A 96: 3120-3125.
5. Fuchs E, Tumbar T, Guasch G (2004) Socializing with the neighbors: stem cells and their niche. Cell 116: 769-778.
6. Weissman IL (2000) Stem cells: units of development, units of regeneration, and units in evolution. Cell 100: 157-168.
7. Houghton J, Morozov A, Smirnova I, Wang TC (2006) Stem cells and cancer. Semin Cancer Biol.
8. Burkert J, Wright NA, Alison MR (2006) Stem cells and cancer: an intimate relationship. J Pathol 209: 287-297.
9. Jordan CT, Guzman ME, Noble M (2006) Cancer stem cells. N Engl J Med 355: 1253-1261.
10. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
11. Jones RJ, Matsui WH, Smith BD (2004) Cancer stem cells: are we missing the target? J Natl Cancer Inst 96: 583-585.
12. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF (2004) Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14: 43-47.
13. Barnes DJ, Melo JV (2006) Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic mycloid leukemia. Cell Cycle 5: 2862-2866.
14. Holyoake T, Jiang X, Eaves C, Eaves A (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic mycloid leukemia. Blood 94: 2056-2064.
15. Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, et al. (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97: 720-728.
16. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to ST1571 in vitro. Blood 99: 319-325.
17. Melo JV, Hughes TP, Apperley JF (2003) Chronic myeloid leukemia. Hematology (Am See Hematol Educ Program). pp 132-152.
18. Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103: 4010-4022.
19. Shet AS, Jahagirdar BN, Verfaillie CM (2002) Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia 16: 1402-1411.
20. Yoshida C, Melo JV (2004) Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int J Hematol 79: 420-433.
21. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340: 1330-1340.
22. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
23. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
24. Daley GQ (2003) Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl cransferase inhibitors. Semin Hematol 40: 11-14.
25. Deininger MW, Druker BJ (2003) Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55: 401-423.
26. John AM, Thomas NS, Mufti GJ, Padua RA (2004) Targeted therapies in myeloid leukemia. Semin Cancer Biol 14: 41-62.
27. O'Dwyer ME, Mauro MJ, Druker BJ (2002) Recent advancements in the treatment of chronic myelogenous leukemia. Annu Rev Med 53: 369-381.
28. Tauchi T, Ohyashiki K (2004) Molecular mechanisms of resistance of leukemia to imatinib mesylate. Leuk Res 28 Suppl 1: S39-45.
29. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, et al. (2006) Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med 12: 1181-1184.
30. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, et al. (2005) Dynamics of chronic mycloid leukaemia. Nature 435: 1267-1270.
31. Cortes J, O'Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104: 2204-2205.
32. Higashi T, Tsukada J, Kato C, Iwashige A, Mizobe T, et al. (2004) Imatinib mesylate-sensifive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 76: 275-278.
33. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, et al. (2006) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than two years. Blood.
34. Daub H, Specht K, Ullrich A (2004) Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov 3: 1001-1010.
35. Druker BJ (2003) Overcoming resistance to imatinib by combining targeted agents. Mol Cancer Ther 2: 225-226.
36. Druker BJ (2004) Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91: 1-30.
37. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, et al. (2003) Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4: 75-85.
38. Nardi V, Azam M, Daley GQ (2004) Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 11: 35-43.
39. Shannon KM (2002) Resistance in the land of molecular cancer therapeutics. Cancer Cell 2: 99-102.
40. Yee KW, Keating A (2003) Advances in targeted therapy for chronic myeloid leukemia. Expert Rev Anticancer Ther 3: 295-310.
41. Komarova NL, Wodarz D (2005) Drug resistance in cancer: principles of emergence and prevention. Proc Natl Acad Sci U S A 102: 9714-9719.
42. Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H (2007) New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 44: 25-31.
43. Coldman AJ, Goldie JH (1986) A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol 48: 279-292.
44. Gyllenberg M, Webb GF (1987) Age-size structure in populations with quiescence. Mathematical Biosciences 86: 67-95.
45. Gyllenberg M, Webb GF (1989) Quiescence as an explanation of Gompertzian tumor growth. Growth Dev Aging 53: 25-33.
46. Gyllenberg M, Webb GF (1990) A nonlinear structured population model of tumor growth with quiescence. J Math Biol 28: 671-694.